Two Distinct Subtypes of Nasal-type NK/T Cell Lymphoma: Clinical Features and Treatment Outcome According to Primary Site of the Nasal Cavity or Waldeyer's Ring

H. Fang,Y. Li,Q. Liu,S. Qi,J. Jin,W. Wang,Y. Liu,Y. Song,S. Wang,Z. Yu

DOI: https://doi.org/10.1016/j.ijrobp.2008.06.1397

2008-01-01

Abstract:To define the clinical characteristics, prognosis and treatment outcome for nasal-type NK/T cell lymphoma of Waldeyer's ring (WR-NKTL) and nasal NK/T cell lymphoma (N-NKTL). Ninety-five patients with WR-NKTL and 145 patients with N-NKTL were systematically reviewed. There were 134 stage I, 82 stage II, 13 stage III, and 11 stage IV. For patients with stage I and II diseases, 145 patients were treated with combined modality therapy, 61 with radiotherapy alone, and 10 with chemotherapy alone. Twenty-four patients with advanced disease were primarily treated with CT with or without RT to the primary tumor. WR-NKTL had many similarities to the prototype of N-NKTL including a young male predominance, frequent B symptoms and adjacent organ extension, good performance, low risk prognostic factors according to the IPI, and highly sensitive to RT. However, it showed striking distinct differences in clinical features such as a propensity of nodal involvement, more advanced stage disease (stage II-IV), and less frequency of evaluated LDH, intermediate sensitive to conventional CT, and favorable prognosis. Patients with WR-NKTL had significantly higher overall response rates (CR+ PR), but lower SD and PD rates after initial chemotherapy (p = 0.000). The 5-year OS and PFS were comparable for patients with WR-NKTL and N-NKTL although there was more advanced disease with WR-NKTL. The corresponding 5-year OS and PFS for each entire group were 65% and 47% for WR-NKTL, and 67% and 56% for N-NKTL, respectively (p = 0.539 for OS, 0.722 for PFS). However, for patients with stage II disease, WR-NKTL carried a favorable prognosis as compared to N-NKTL, with 5-year OS and PFS of 73% and 55% for WR-NKTL, and 20% and 18% for N-NKTL (p = 0.000 for OS and PFS). For patients with stage I disease, there was no significant difference in OS and PFS between patients with WR-NKTL and N-NKTL (5-year OS, 88% vs. 79%, p = 0.381; 5-year PFS, 66% vs. 65%, p = 0.417). The most common site of treatment failure was both lymph nodes and extranodal sites for patients with WR-NKTL, whereas it was extranodal organs for those with N-NKTL. Our results clearly indicate that WR-NKTL is a new entity with distinct clinical features and treatment options.